Skip to content
Vironova MiniTEM™
Vironova MiniTEM™

Press release -

MiniTEM™ for quality analysis of phage preparations - poster presentation at the Phage Future Congress 2019

On January 29th Vironova will be attending The Phage Futures Congress in Washington D.C. to follow key industry trends together with peers from biotech companies and academia. Experts from regulatory bodies, pharmaceutical companies and government institutions will discuss how to actively progress clinical science and viable phage application routes to market.

Bacteriophages are a promising alternative treatment for (antimicrobial resistant) bacterial infections. A simple method to determine the stability and integrity of phage cocktails over time is needed to guarantee the success of phage treatment.

Meet our US Sales Development Managers Chris Bishop, Ulla Sundberg, and Ph.D and Senior Scientsit Vanessa Carvalho from Vironova in the dedicated poster area, where we have a poster presentation to show the potential of MiniTEM™. Our desktop low-voltage (25 keV) transmission electron microscope.

MiniTEM is used to automatically acquire images of phage cocktails of different integrities and Vironova have developed a script that detects, and provides morphological measurements of, phages particles. The direct visual information on sample content and particle morphology were key for understanding the number and intactness of the different phage particles comprising the cocktail targeting Escherichia coli.

In short, at our poster session at the Phage Futures Congress, we will show that MiniTEM™ can be applied for quality analysis of phage preparations.

Meet Vironova at The Phage Congress 2019 in Washington DC

For more information, contact us at

Related links



Vironova is a Swedish biotechnology company providing comprehensive, hardware, software and services for the analysis of nanoparticles. Vironova revolutionizes access to transmission electron microscopy (TEM)-based image analysis in biopharmaceutical development. Our solution enables automated analyses for faster and better-informed decisions to secure robust bioprocessing and final product quality.

The Vironova offering comprises:

  • Cost effective, fast Electron Microscopy (EM) services enabled by the in-house developed Vironova Analyzing Software (VAS) designed for semi-automated nanoparticle analysis
  • Viral clearance testing performed in GLP and BSLIII certified laboratories
  • MiniTEM™, a bench-top Transmission Electron Microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics.

Press contacts

Josefina Nilsson

Josefina Nilsson

Press contact CEO

Related events

Vironova making the invisible visible today.

Founded in Stockholm in 2005, Vironova is a world leading partner to the global life science community in the development of novel therapies for tomorrow. By combining hardware and software solutions for advanced electron microscopy analysis, we support our partners through the whole value chain. From initial sample preparation to imaging and final analytical result, our dedicated team provide insightful and actionable data. We empower clients to make better-informed decisions, to create value and ensure safety for patients worldwide.

Market insight and need
The life science market is shifting. Recent successes in genetic medicine have paved the way for a broader wave of therapies and next-generation technologies. As conventional therapies mature, cell and gene therapies are emerging as the future of biopharmaceuticals, representing a pivotal approach to treat previously uncurable diseases and conditions. As a result, the global cell and gene therapy market is expected to grow from 3 to 27 billion dollars by 2025.

Development of novel therapies is a highly regulated, costly and time critical process – setting high standards for secure, reliable and intuitive systems across the entire production line. Vironova is in pole position to capture value and growth opportunities in this ever-evolving landscape. Transmission electron microscopy (TEM) paired with our intelligent software and experience, is the leading method capable of producing a reliable and accurate analysis for the development of novel therapies.

The problem we solve
TEM has previously been an expensive and complex practice to use in gene therapy, vaccine and drug development. At Vironova, we focus on supporting our partners by lowering technical thresholds, minimizing analytical complexity and provide business critical insights for the development of biopharmaceuticals targeting previously untreatable conditions.
We are experts in what we do and put technology and innovation at our core. From initial sample preparation to imaging and final analytical result, our dedicated team will cut time and cost to market for our clients, and ultimately create value for patients worldwide. We are on a mission to build trust in the therapies of tomorrow by making the invisible visible today.

The offer
Vironova provides fast and cost-effective electron microscopy services enabled by our own software and hardware. Our services are performed in the world’s only GMP-certified TEM laboratory, creating reliable and traceable results. This makes us the only company with a full-service value chain offer from start to finish.
By combining deep industry expertise and data-driven insights, we help clients solve real needs by making the subvisible accessible. With over 200 established customer relationships, Vironova is a leading partner for the life science industry. We have a strong acquisition pipeline of new clients and deep inroads with the global research community.

Future plan and viability
Our vision is clear, we want to set the golden standard for safe and effective therapy development. We ensure that our clients are placing their trust in the right therapeutic candidates, by removing subjectivity from the picture. Vironova is a key niche player in the life sciences market and we are well positioned to create value in an industry with strong financial characteristics. Society is currently taking the first steps towards unleashing the full potential of gene and cell therapies. Vironova makes the journey safer by providing a clear image of the future.